Summary
GlobalData's pharmaceutical report offering, "Herpes Simplex-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global herpes simplex therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

GlobalData finds that the global herpes simplex market was worth approximately $2.9 billion in 2009. The global herpes simplex therapeutics market is expected to grow at a CAGR of 11.1% between 2009 and 2016. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently the therapeutic regimen for Herpes Simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC products such as Abreva and Aviralex. This market is a significantly genericized market with many brands across the major seven geographies.

Scope
-Annualized global herpes simplex market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
-Key geographies covered in this report include the US (United States), the UK (united Kingdom), Italy, Spain, Germany, France and Japan.
-Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
-Analysis of the current and future market competition in the global herpes simplex market. Key market players covered are BioAlliance Pharma, Nutra Pharma Corporation and AiCuris GmbH & Co. KG.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with herpes simplex therapeutics.

Reasons to buy
-Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global herpes simplex market.
-Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global herpes simplex market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolios and create effective   counter-strategies to gain the competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global herpes simplex market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Herpes Simplex Therapeutics Market: Market Characterization 5
2.1 Overview 5
2.2 Herpes Simplex Therapeutics Market Size 5
2.3 Herpes Simplex Therapeutics Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Herpes Simplex Therapeutics Market 7
2.4.1 Drivers for the Herpes Simplex Therapeutics Market 7
2.4.2 Barriers for the Herpes Simplex Therapeutics Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Herpes Simplex Therapeutics Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market 11
3.3.1 Zovirax (Acyclovir) 11
3.3.2 Famvir (Famciclovir) 12
3.3.3 Valtrex (Valacyclovir) 13
3.4 Key Takeaway 15
4 Herpes Simplex Therapeutics Market: Pipeline Assessment 16
4.1 Overview 16
4.1.1 Technology Trends Analytical Framework 16
4.2 Herpes Simplex Therapeutics-Promising Drugs under Clinical Development 17
4.3 Molecule Profiles for Promising Drugs under Clinical Development 18
4.3.1 RPI-78M 18
4.3.2 BA-021 (Acyclovir Lauriad) 18
4.3.3 AIC316 19
4.4 Herpes Simplex Therapeutics Market-Pipeline Assessment by Mechanism of Action 20
4.5 Herpes Simplex Therapeutics Market-Pipeline Assessment by Clinical Phases of Development 20
4.5.1 Herpes Simplex Therapeutics-Phase III Clinical Pipeline 21
4.5.2 Herpes Simplex Therapeutics-Phase II Clinical Pipeline 21
4.5.3 Herpes Simplex Therapeutics-Phase I Clinical Pipeline 22
4.5.4 Herpes Simplex Therapeutics-Preclinical Pipeline 22
4.5.5 Herpes Simplex Therapeutics-Discovery Pipeline 22
4.6 Discontinued/Suspended Drugs for Herpes Simplex 22
4.7 Key Takeaway 23
5 Herpes Simplex Therapeutics Market: Implications for Future Market Competition 24
6 Herpes Simplex Therapeutics Market: Key Players in the Herpes Simplex Therapeutics Market 26
6.1 Bioalliance Pharma 26
6.1.1 Overview 26
6.1.2 Business Description 26
6.1.3 Anti-Viral Pipeline Portfolio 27
6.1.4 Herpes Simplex Pipeline Portfolio 27
6.2 Nutra Pharma Corporation 28
6.2.1 Overview 28
6.2.2 Business Description 28
6.2.3 Anti-Viral Pipeline Portfolio 29
6.2.4 Herpes Simplex Pipeline Portfolio 29
6.3 AiCuris GmbH and Co. KG 30
6.3.1 Overview 30
6.3.2 Herpes Simplex Pipeline Portfolio 30
7 Herpes Simplex Therapeutics Market: Appendix 31
7.1 Definitions 31
7.2 Acronyms 31
7.3 Research Methodology 31
7.3.1 Coverage 32
7.3.2 Secondary Research 32
7.3.3 Forecasting 33
7.3.4 Primary Research 35
7.3.5 Expert Panel Validation 36
7.4 Contact Us 36
7.5 Disclaimer 36
7.6 Sources 36

List of Tables
1.1 List of Tables
Table 1: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Table 2: Herpes Simplex Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 7
Table 3:    Herpes Simplex Therapeutics Market, Global, Major Marketed Products Comparison in the Herpes Simplex Therapeutics Market , 2010 15
Table 4:    Herpes Simplex Therapeutics Market, Global,  Most Promising Molecules under Clinical Development, February 2010 17
Table 5: Herpes Simplex Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 21
Table 6: Herpes Simplex Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 21
Table 7: Herpes Simplex Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 22
Table 8: Herpes Simplex Therapeutics Market, Global, Preclinical Pipeline, 2010 22
Table 9: Herpes Simplex Therapeutics Market, Global, Discovery Pipeline, 2010 22
Table 10: Herpes Simplex Therapeutics Market, Global, List of Discontinued Drugs for Herpes Simplex, 2010 22
Table 11: Herpes Simplex Therapeutics Market, Global, Bioalliance Pharma Anti-Viral Pipeline Portfolio, 2010 27
Table 12: Herpes Simplex Therapeutics Market, Global, Bioalliance Pharma Herpes Simplex Pipeline Portfolio, February 2010 27
Table 13: Herpes Simplex Therapeutics Market, Global, Nutra Pharma Corporation Anti-Viral Pipeline Portfolio, 2010 29
Table 14: Herpes Simplex Therapeutics Market, Global, Nutra Pharma Corporation Anti-Viral Pipeline Portfolio, 2010 29
Table 15: Herpes Simplex Therapeutics Market, Global, AiCuris GmbH & Co. KG Herpes Simplex Pipeline Portfolio, 2010 30

List of Figures
1.2 List of Figures
Figure 1: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Figure 2: Herpes Simplex Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 7
Figure 3: Herpes Simplex Therapeutics Market, Global, Opportunity and Unmet Need in the Herpes Simplex Therapeutics Market, 2010 8
Figure 4: Herpes Simplex Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products in Herpes Simplex Therapeutics Market, 2010 10
Figure 5: Herpes Simplex Therapeutics Market, Global, Technology Trends Analytic Framework of the Herpes Simplex Therapeutics Pipeline, 2010 16
Figure 6: Herpes Simplex Therapeutics Market, Global, Technology Trends Analytic Framework  of the Herpes Simplex Therapeutics Pipeline-Description, 2010 17
Figure 7: Herpes Simplex Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 20
Figure 8: Herpes Simplex Therapeutics Market, Global, Clinical Pipeline by Phases of Development, 2010 20
Figure 9: Herpes Simplex Therapeutics Market, Global, Implications for Future Market Competition in the Herpes Simplex Therapeutics Market, 2010 24
Figure 10: Herpes Simplex Therapeutics Market, Global, Clinical Pipeline by Company, 2010 26
Figure 11: GlobalData Methodology 32
Figure 12: GlobalData  Market Forecasting Model 35